A detailed history of Jane Street Group, LLC transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 107,572 shares of TSHA stock, worth $216,219. This represents 0.0% of its overall portfolio holdings.

Number of Shares
107,572
Previous 128,124 16.04%
Holding current value
$216,219
Previous $286,000 24.48%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.01 - $2.46 $41,309 - $50,557
-20,552 Reduced 16.04%
107,572 $216,000
Q2 2024

Aug 14, 2024

BUY
$2.04 - $4.17 $141,245 - $288,722
69,238 Added 117.58%
128,124 $286,000
Q1 2024

May 15, 2024

BUY
$1.43 - $3.25 $23,749 - $53,976
16,608 Added 39.28%
58,886 $169,000
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $56,229 - $121,760
42,278 New
42,278 $74,000
Q4 2020

Feb 17, 2021

SELL
$19.14 - $28.13 $444,698 - $653,572
-23,234 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$22.4 - $24.47 $520,441 - $568,535
23,234 New
23,234 $520,000

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $97.2M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.